Tradestie Institutional Equity Comparison Engine
CDT vs STRO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
STRO Overall Edge
STRO Captures Institutional Edge (3โ1 Pillars ยท 6โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Sutro Biopharma, Inc. (STRO) driven by superior Valuation, Momentum & Technical, Options & Structure while CDT counters with relative strength in Growth & Margin. Fundamentally, CDT trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus STRO at 10.0x Forward P/E and -254.7% operating margin (-6.1% YoY). In options structure, CDT sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against STRO sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
STRO
CDT N/M vs STRO 10.0x Fwd P/E
Growth & Margin Winner
CDT
Op Margin 0.0% vs -254.7% ยท YoY +0.0% vs -6.1%
Momentum & Technical Winner
STRO
1Y -86.8% vs +845.0% ยท 52W Pos 2% vs 18%
Options & Structure Winner
STRO
BREAKDOWN (N/A IV) vs UNCLASSIFIED (<1st %ile IV)
CDT
NASDAQ
CDT Equity Inc. Common Stock
Pharmaceutical Preparations
$0.23
-13.89% 1D
Market Cap
$507,528
1M Return
+76.79%
1Y Return
-86.78%
Forward P/E
N/M
Unified AI Score
31.6 / 100
SELL
Tech 15.0
Fund 37.0
Flow 50.0
Mom 54.0
STRO
NASDAQ
Sutro Biopharma, Inc.
Biological Products, (No Diagnostic Substances)
$8.60
-1.38% 1D
Market Cap
$144.8M
1M Return
-16.42%
1Y Return
+845.05%
Forward P/E
10.0x
Unified AI Score
44.1 / 100
HOLD
Tech 30.0
Fund 48.0
Flow 50.0
Mom 68.9
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CDT -86.78%
STRO +845.05%
Spread: +931.83 pp (STRO Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CDT TTM Op. Margin: 0.0%
STRO TTM Op. Margin: -254.7%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CDT vs STRO. Trailing 12-month operating profitability (CDT 0.0% vs STRO -254.7%) and valuation multiples (CDT N/M vs STRO 10.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CDT | STRO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $507,528 | $144.8M | Larger Scale | STRO |
| Trailing P/E Ratio Valuation | N/M | 10.0x | Lower Multiple | STRO |
| Forward P/E Ratio Valuation | N/M | 10.0x | Lower Multiple | STRO |
| Revenue Growth (YoY) Growth | +0.0% | -6.1% | Higher Growth | CDT |
| Operating Margin (TTM) Profitability | 0.0% | -254.7% | Higher Margin | CDT |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -69.7% | -1810.0% | Higher ROE | CDT |
| 52-Week Range Position Momentum | 2% ($0โ$11) | 18% ($1โ$44) | Stronger Trend | STRO |
| Beta / 30D Volatility Risk Regime | -17.75ฮฒ ยท 10175% Vol | 1.46ฮฒ ยท 76% Vol | Lower Realized Risk | STRO |
| Unified Institutional Score Composite Signal | 31.6 / 100 (SELL) | 44.1 / 100 (HOLD) | Higher Composite | STRO |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CDT vs STRO Buy Guide
CDT
BREAKDOWN
163d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
STRO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CDT nor STRO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.